Research programme: allergy therapy - Maxygen/Karolinska Institute
Latest Information Update: 21 Aug 2007
At a glance
- Originator Karolinska Institute; Maxygen
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hypersensitivity
Most Recent Events
- 08 Dec 2003 No development reported - Preclinical for Allergy in Sweden (unspecified route)
- 08 Dec 2003 No development reported - Preclinical for Allergy in USA (unspecified route)
- 01 Aug 2001 New profile